Dr Dennis CJJ Bergmans

• Intensive Care Center Maastricht
• Maastricht University Medical Center+
• The Netherlands

If any particles are left behind gastritis symptoms in puppies prevacid 30 mg order amex, particularly in the case of lime gastritis nutrition diet purchase prevacid 15 mg fast delivery, these should be removed carefully with a swab stick gastritis healing process order 15 mg prevacid overnight delivery. Contaminated and necrosed corneal epithelium should be removed with a cotton swab stick chronic gastritis meaning purchase prevacid visa. Maintenance of favourable conditions for rapid and uncomplicated healing by frequent application of topical atropine gastritis diet 6 pack order prevacid cheap online, corticosteroids and antibiotics. Prevention of symblepharon can be done by using a glass shell or sweeping a glass rod in the fornices twice daily. When cornea is affected, it should be treated with atropine, steroids and antibiotics. These may cause (i) photo-ophthalmia (see page 111) and (ii) may be responsible for senile cataract. These are caused following radiotherapy to the tumours in the vicinity of the eyes. The common ocular lesions include (i) radiation keratoconjunctivitis; (ii) radiation dermatitis of lids; and (iii) radiation cataract. Topical instillation into the conjunctival sac this is the most commonly employed mode of administration for ocular therapeutics. The drugs can be administered topically in the form of eyedrops, ointments, gels, ocuserts and with the help of soft contact lenses. Eyedrops may be in the form of aqueous solutions (drug totally dissolved) or aqueous suspensions (drug is present as small particles kept suspended in the aqueous medium) or oily solutions. Topical application in the form of an eye ointment increases the bioavailability of the drug by increasing tissue contact time and by preventing dilution and quick absorption. These can be placed in the upper or lower fornix up to a week and allow a drug to be released at a relatively constant rate. These are very good for delivering higher concentrations of drugs in emergency treatment. A pre-soaked soft contact lens in 1 percent pilocarpine has been found as effective as 4 percent pilocarpine eyedrops in patients with acute angle closure glaucoma. Soft contact lenses are also used to deliver antibiotics and antiviral drugs in patients with corneal ulcers. Systemic administration Topically instilled medications largely penetrate intraocularly through the cornea. The main barrier through cornea is its epithelium, which is lipophilic, and crossed readily by non-polar drugs. So following features will allow better penetration of drugs through the cornea: Drugs which are soluble both in water and fats. Pro-drug forms are lipophilic and after absorption through epithelium are converted into proper drugs which can easily pass through stroma. Agents that reduce surface tension increase corneal wetting and therefore present more drug for absorption. Periocular injections the systemic routes include oral intake and intramuscular and intravenous injections. The intraocular penetration of systemically administered drugs mainly depends upon the blood-aqueous barrier. The passage through blood-aqueous barrier in turn is influenced by the molecular weight and the lipid solubility of the drug. Further, the drugs which cannot penetrate the cornea owing to large-sized molecules can easily pass through the sclera. Anterior sub-Tenon injections are used mainly to administer steroids in the treatment of severe or resistant anterior uveitis. Posterior sub-Tenon injections are indicated in patients with intermediate and posterior uveitis. These are used to deliver drugs for optic neuritis, papillitis, posterior uveitis and also for administering retrobulbar block anaesthesia. Peribulbar anaesthesia has almost replaced retrobulbar and facial block anaesthesia. Intraocular injections Antimicrobial drugs are the greatest contribution of the present century to therapeutics. Depending on the type of action, these can be either bacteriostatic or bactericidal. A few common antimicrobials described here are grouped on the basis of their chemical structure. In ophthalmology, these are used topically and systemically in the treatment of chlamydial infections, viz. They are also helpful as an adjunct to pyrimethamine in the treatment of toxoplasmosis. These include: intracameral injection (into the anterior chamber), and intravitreal injection (into the vitreous cavity). All beta-lactam antibiotics act by interfering with the synthesis of bacterial cell wall. This is an intramuscular depot preparation which provides tissue levels up to 24 hours. It is resistant to the penicillinase produced by some strains of Proteus, Pseudomonas and coliform organisms. Its oral absorption is better than ampicillin and thus higher and more sustained blood levels are produced. By convention these have been categorised into three generations of broadly similar antibacterial and pharmacokinetic properties: 1. These are very active against gram- positive cocci and thus have useful antistaphylococcal activity. These have antistaphylococcal activity and are also effective against certain gram-negative organisms. These are mainly effective against gramnegative organisms but not against staphylococci. If these are continued for more than 2 weeks, thrombocytopenia, neutropenia, interstitial nephritis or abnormal liver function tests may occur. Aminoglycosides these are bactericidal and act primarily against gramnegative bacilli. It is nephrotoxic, therefore, its dose must be precisely calculated according to body weight and renal function. It is 2-4 times more active against Pseudomonas aeruginosa and Proteus as compared to gentamicin. It is recommended as a reserve drug for hospital acquired gram-negative bacillary infections where gentamicin resistance is increasing. Commonly used fluoroquinolones Generation and drug First generation Ciprofloxacin Preparation and doses Topical 0. It is also a broad-spectrum antibiotic, primarily bacteriostatic, effective against gram-positive as well as gram-negative bacteria, rickettsiae, chlamydiae and mycoplasma. Therefore, on systemic administration, it enters the eye in therapeutic concentration. Fourth generation Gatifloxacin Moxifloxacin these are powerful bactericidal agents, but rarely used systemically due to toxicity. Antiviral drugs used in ophthalmology can be grouped as below: For herpes simplex virus infection Idoxuridine Vidarabine Trifluridine Acyclovir Famiciclovir For herpes zoster virus infection Acyclovir Famiciclovir Valaciclovir Vidarabine Sorvudine Fluoroquinolones are potent synthetic agents having broad spectrum of activity against gram-positive and gram negative-organisms. Dose: It is used 5 times a day till epithelization occurs and then reduced to once or twice daily for 4-5 days to prevent recurrences. Side-effects are superificial punctate keratitis and irritation on prolonged application. It is a purine nucleoside, Mechanism of action: It blocks nucleic acid synthesis by preventing conversion of cytosine ribose to cytosine deoxyribose. It has proved to be an extremely safe and effective agent and is effective in most forms of herpes simplex and herpes zoster infections. It is available as 3 percent ophthalmic ointment and also as tablet for oral use and injection for intravenous use. Indications and doses: (a) Topical 3 percent ointment is used 5 times a day for epithelial as well as stromal herpes simplex keratitis (b) Oral acyclovir four tablets of 200 mg each, 5 times a day for 5-7 days, may be considered in following situations: (i) After penetrating keratoplasty in patients suffering from herpes simplex keratitis. These are non-toxic, species-specific proteins possessing broad-spectrum antiviral activity. These preparations may be useful in the treatment or prophylaxis of certain viral diseases especially in patients with immune deficiencies. Dose: 5 mg/kg body weight every 12 hours for 2-3 weeks, followed by a permanent maintenance dose of 5 mg/ kg once daily for 5 out of 7 days. These can be broadly classified on the basis of their chemical structure into polyene antibiotics, imidazole derivatives, pyrimidines and silver compounds. Amphotericin B may be given intravitreally or/ and intravenously for treatment of intraocular infections caused by Candida, Histoplasma, Cryptococcus and some strains of Aspergillus and others. It is a broad-spectrum antifungal drug having activity against Candida, Aspergillus, Fusarium and Cephalosporium. Topical application of 5 percent pimaricin suspension produces effective concentrations within the corneal stroma but not in intraocular fluid. It has a medium level of activity in ocular infections caused by Candida or Aspergillus isolates. Because of its narrow spectrum and poor intraocular penetration its use is restricted. Various imidazole derivatives available for use in ocular fungal infections include: miconazole, clotrimazole, ketoconazole, econazole and itraconazole. It possesses a broad antifungal spectrum and is fungicidal to various species of Candida, Aspergillus, Fusarium, Cryptococcus, Cladosporium, Trichophyton and many others. Topical (1%) and subconjunctival (10 mg) application of miconazole produces high levels of the drug in the cornea which is more dramatic in the presence of epithelial defect. Its 1 percent suspension is effective topically and is the treatment of choice in Aspergillus infections of the eye. It also has broad-spectrum antifungal activity and is used topically as 1 percent econazole nitrate ointment. Becaue of its poor intraocular penetration, it is effective only in superficial infections of the eye. It is given as single oral dose of 200-400 mg daily up to at least one week after the symptoms have disappeared. It is an adjunctive systemic antifungal agent in fungal keratitis complicated by endophthalmitis. Parasympathomimetic drugs (Miotics) Parasympathomimetics, also called as cholinergic drugs, either imitate or potentiate the effects of acetylcholine. Classification this group includes flucystosine, which is a fluorinated salt of pyrimidine. Silver compounds Depending upon the mode of action, these can be classified as follows: 1. Indirect-acting parasympathomimetics or cholinesterase inhibitors: As the name indicates these drugs act indirectly by destroying the enzyme cholinesterase; thereby sparing the naturallyacting acetylcholine for its actions. Mechanism of action Combination of silver with sulfonamides and with other anti-microbial compounds significantly increases the activity against bacterial and fungal infections. Most frequently used is silver sulphadiazine which is reported to be highly effective against Aspergillus and Fusarium species. The mechanical contraction of the pupil moves the iris away from the trabecular meshwork. Systemic side-effects noted are: bradycardia, increased sweating, diarrhoea, excessive salivation and anxiety. Sympathomimetic drugs Sympathomimetics, also known as adrenergic agonists, act by stimulation of alpha, beta or both the receptors. Indications: (i) Primary open-angle glaucoma; (ii) Acute angle-closure glaucoma; (iii) Chronic synechial angle-closure glaucoma. Available preparations and dosage are: (a) Eyedrops are available in 1%, 2% and 4% strengths. The onset of action occurs in 20 minutes, peak in 2 hours and duration of effect is 4-6 hours. Pilo-20 is generally used in patients controlled with 2 percent or less concentration of eyedrops; and pilo-40 in those requiring higher concentration of eyedrops. Increased aqueous outflow results by virtue of both alpha and beta-receptor stimulation. Decreased aqueous humour production occurs due to stimulation of alpha-receptors in the ciliary body. Systemic side-effects include hypertension, tachycardia, headache, palpitation, tremors, nervousness and anxiety. Local side-effects are burning sensation, reactive hyperaemia of conjunctiva, conjunctival pigmentation, allergic blepharo conjunctivitis, mydriasis and cystoid macular oedema (in aphakics). This direct-acting sympathomimetic drug stimulates both alpha and beta- adrenergic receptors. It is a prodrug which is converted into epinephrine after its absorption into the eye. It is more lipophilic than epinephrine and thus its corneal penetration is increased by 17 times. Dosage: It has a peak effect of 2 hours and action lasts for 12 hours; so it is administered twice daily. It is of limited use for long-term administration because of the high rate of ocular side-effects. Timolol and levobunolol are non-selective beta-1 (Cardiac) and beta-2 (smooth muscle, pulmonary) receptor blocking agents. These include burning and conjunctival hyperaemia, superficial punctate keratopathy and corneal anaesthesia.

An equal number of patients have infarction of the retinal vasculature secondary to antiphospholipid antibodies gastritis diet nz order prevacid 15 mg. Table 9 shows the frequency of various manifestations both at disease onset and at anytime during the disease course gastritis in toddlers buy prevacid 30 mg with visa. Presence of one or more of these features or the involvement of at least two different organs in young women should always raise the possibility of lupus gastritis chest pain purchase prevacid 15 mg visa. However gastritis diarrhea buy 30 mg prevacid free shipping, many of these features are not unique to lupus but could be seen in other infectious gastritis diet 17 effective prevacid 15 mg, metabolic, malignant, and other systemic rheumatic diseases. The recognition that systemic rheumatic diseases have several common features which makes a specific diagnosis difficult has led to the concept of the Table 9 Frequency of various manifestations of systemic lupus erythematosus at disease onset and at any time during the disease 495 20 Eular Fpp. A careful history for manifestations of lupus in the past and a careful examination together with serology may help recognise the disease. Patients presenting with fever or splenomegaly/ lymphadenopathy must be differentiated from infectious diseases or lymphoma. Lupus may present with localised or generalised lymphadenopathy or splenomegaly, but the size of lymph nodes is rarely >2 cm while splenomegaly is mild-to-moderate. In patients presenting with neurological symptoms, infections, cerebrovascular accidents or immune mediated neurologic diseases such as multiple sclerosis or Guillain-Barré disease must be considered. Proteinuria may increase during pregnancy in women with underlying kidney disease. Differentiation of pre-eclampsia from lupus renal activity is not difficult in most cases. Very low serum complement, active urine sediment, and evidence of generalised lupus activity favour the latter. Other features such as hypertension, thrombocytopenia, rise in serum uric acid levels, and proteinuria may be observed in both conditions. Low grade activation of the classic complement pathway may be attributable to pregnancy alone. These conditions are associated with increased risk of miscarriage, stillbirth, premature delivery, intrauterine growth restriction, and fetal heart block. The most serious complication in the neonate is complete heart block, which occurs in up to 2% of such pregnancies. Once a woman has given birth to an infant with congenital heart block, the recurrence rate is about 15%. In general, the same principles are applied in the management of paediatric lupus; however, the special needs of this population also have to be taken into consideration. The presence of generalised lupus activity and active urine sediment and significantly low serum complement favours lupus nephritis Table 10 An approach to the management of pregnancy in systemic lupus erythematosus 14 Drug-induced lupus A variety of drugs have been identified as being definite, probable or possible causes of lupus (table 11). Critical questions confronting the clinician are: (1) whether the event is related to lupus; and (2) whether in the presence of lupus the management should differ. Poor compliance, low education level, severity of the underlying disease, and higher damage scores are risk factors for hospitalisation. In the case of the lungs, a diagnosis of acute lupus pneumonitis can be made after rigorously excluding infections in patients presenting with features resembling infectious pneumonia. A high index of suspicion should be maintained for the young female patient presenting with unexplained pulmonary infiltrates. Alveolar haemorrhage is also a serious but rare complication of lupus with high morbidity and mortality. Respiratory failure may occur, and more than half of affected patients in most series required mechanical ventilation. Patients with alveolar haemorrhage usually have lupus nephritis as a pre-existing condition. Cases of left ventricular free wall rupture, acute mitral regurgitation following rupture of chordae tendinae, and aortic dissection have been described. Cerebrovascular accidents presenting acutely with hemiplegia, aphasia, 497 20 Eular Fpp. Patients present with weakness or paralysis, bilateral sensory deficits, and impaired sphincter control. Because of the poor prognosis early diagnosis and aggressive therapy are important. In view of the high mortality in this subgroup, patients with a high index of suspicion should undergo early laparotomy. However, their role in the early diagnosis, monitoring of patients with mild, stable diseases, and the referral for patients with unstable or moderate to severe disease is essential. Guidelines for the initial assessment and frequency of monitoring for general use are shown in table 12. Infections, coronary artery disease, and orthopaedic management of osteonecrosis were prominent reasons for hospitalisation. Moreover, a significant number of patients (10­20% in tertiary referral centres) do not respond adequately to immunosuppressive therapies. Table 12 Recommended initial assessment and monitoring of systemic lupus erythematosus 499 20 Eular Fpp. The evaluation of a lupus patient who receives immunosuppressive therapy and presents with symptoms or signs suggestive of infection possesses diagnostic and therapeutic challenges. Findings that favour the diagnosis of infection include the presence of shaking chills, leucocytosis and/or neutrophilia (especially in the absence of steroid therapy), increased numbers of band forms or metamyelocytes on peripheral blood smear, and concomitant immunosuppressive therapy. Pending microbiology results, adequate antimicrobial therapy (including broad spectrum antibiotics in suspected nosocomial infection) is recommended to reduce adverse outcomes. Vertebral compression fractures are common, especially as the age of patients increases. The risk for haematological malignancies may increase after exposure to immunosuppressive medications, particularly after a period of 5 years following cessation of therapy. In such cases, an aggressive investigation is warranted with appropriate imaging studies and, potentially, lymph node biopsy. These comorbidities include infections (urinary track infections (B), other infections (C)), atherosclerosis (B), hypertension (B), dyslipidaemias (B), diabetes (C), osteoporosis (C), avascular necrosis (C), malignancies (especially non-Hodgkin lymphoma) (B). Minimisation of risk factors together with a high index of suspicion, prompt evaluation, and diligent follow-up of these patients is recommended. Pregnancy may increase lupus disease activity but these flares are usually mild (B). Patients with lupus nephritis and anti-phospholipid antibodies are more at risk of developing preeclampsia and should be monitored more closely (B). These conditions are associated with an increase of the risk of miscarriage (B), stillbirth (B), premature delivery (B), intrauterine growth restriction (C), and fetal heart block (B). Prednisolone (D), azathioprine (D), hydroxychloroquine (A), and low dose aspirin (D) may be used in lupus pregnancies. At present evidence suggests that mycophenolate mofetil, cyclophosphamide and methotrexate must be avoided (D). Lupus nephritis Monitoring Renal biopsy (B), urine sediment analysis (B), proteinuria (B), and kidney function (B) may have independent predictive ability for clinical outcome in therapy of lupus nephritis but need to be interpreted in conjunction. These recommendations-developed not only for the specialists but for all internists-were based on a combined researchbased evidence approach and expert opinion consensus. These patients have been gathered by a European consortium of more than 40 investigators from seven European countries. The general clinical and serologic characteristics of this cohort at the beginning of the study are shown in tables 14 and 15 (Cervera et al 1993). Childhood onset patients were more likely to have severe organ involvement, especially nephropathy, at presentation. Other major manifestations, such as neurologic involvement, thrombocytopenia and haemolytic anaemia, were also common initial features in the childhood onset group. However, during the disease evolution, the pattern was quite similar in childhood onset and adult patients. In the Euro-Lupus Cohort, 90 patients (9%) developed the disease after the age of 50. In contrast, arthritis tended to occur less commonly in men, although the difference was not statistically significant. This atypical presentation is relevant because it can lead to a delay in diagnosis. The prevalence of nephropathy, neurological involvement, thrombocytopenia, vasculitis, and serositis was similar in both groups. For example, the frequency of active lupus nephropathy during the last 5 years was 6. The lower frequencies in the last 5 years probably reflect the effect of therapy and of medical care during the study, but may also reflect natural remissions which may occur with advancing age and the menopause. All p values are a comparison between the frequencies in the 1990­1995 and in the 1995­2000 periods. Table 17 Causes of death in the Euro-Lupus Cohort during the 10 year prospective study (1990­2000) 504 20 Eular Fpp. There is a peak age of onset among women between the late teens and early 40s and a female to male ratio of 9:1. Ethnicity, age at onset, gender, and clinical and immunological features, especially antiphospholipid antibodies at onset, can all influence the prevalence and clinical disease evolution. Factors contributing to mortality include major organ involvement, especially nephropathy, thrombosis, accelerated atherosclerosis, and an increased risk of cancer. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Personnel associated with donor or transfusion related functions shall be suitably trained through a formal training program and supervised in the performance of their prescribed tasks. Personnel shall demonstrate their competency to the satisfaction of the director of the blood bank. All personnel shall have capabilities commensurate with their assigned functions, a thorough understanding of the procedures or control operations they perform, the necessary training or experience, and adequate information concerning the application of pertinent provisions of the rules in this chapter as they relate to their respective duties and responsibilities. The laboratory shall have appropriate equipment for donor and/or recipient testing, component preparation, record keeping, storage and distribution of blood and blood components. All laboratory tests required for proper donor blood processing, not performed by the collecting facility, shall be referred to a laboratory or blood bank licensed in New Jersey or hold an applicable Federal certificate or license. The blood bank shall identify all equipment that is critical to the provision of blood and blood components with unique identification and shall provide a schedule to ensure that all critical equipment is monitored and maintained as required by the manufacturer and in accordance with this chapter. Evidence of periodic evaluation of reagents and equipment including the date of performance; 4. Evidence of periodic evaluation of blood and blood components in accordance with, whichever is more stringent, the current Code of Federal Regulations and/or the current Standards of the American Association of Blood Banks; 5. Evidence of periodic evaluation to determine that policies and procedures are appropriate and are followed; 6. Evidence of daily review of computer maintained error correction records by the blood bank director or supervisor. Evidence of self-evaluation of the clinical appropriateness of licensed activities; and 10. If this function is performed by computer, validation of the computer programs, 8-6 as outlined in N. This review procedure shall be in writing and the procedure shall include tracking of all collected and/or prepared blood and blood components, to assure that: 1. The sequence of the numbers of the blood and blood components drawn are verified and donor numbers for which no donations are available are accounted for; 2. Blood or blood components with positive or questionable test results are not released for allogeneic transfusions; 4. Blood or blood components collected from donors that shall be deferred are not released for allogeneic transfusion or for further manufacture; 5. If required tests are performed by the blood bank, the testing is performed correctly and properly interpreted as determined by at least the following criteria: i. That all blood and blood components from donations that have positive or questionable test results are quarantined until their final disposition is determined or they are destroyed. Records needed to trace a unit of blood or blood component from its source to final disposition shall be kept for at least 10 years after transfusion or five years after the latest expiration date for the individual product, but in no case for less than 10 years. The blood bank shall have a policy addressing the confidentiality of donor and recipient records. Include the date the change was made and the initials of the person making the change. Where instrumentation produces tracings or printouts of results, these tracings or printouts shall be retained in a readily traceable manner and may serve as the workrecord. Prior to use or when modifications are made to the program, validation of all computer programs, including, but not limited to , those dealing with processing, labeling, and distribution of blood and blood components, shall be required as follows: i. To determine if software consistently performs as required and within pre-established limits; and ii. To include review of confidentiality of donor information, security of data and system documentation. Adequate provisions shall be made to safeguard against the eventuality of unexpected electronic loss of data from the computer storage medium. A system shall be in existence which maintains duplicate records on electronic storage media, updates these duplicates continuously and/or transfers electronically stored data periodically to hard copy such as prints or microfiche. The computer shall automatically note, at the time of correction, when corrections are made to verified results. The computer record shall maintain the original verified entry, including the date, time and the identity of the person performing the test. When corrections to verified results are made, both the original and corrected entries shall show the date, time and identity of the person performing the original and corrected records. Records maintained on computer shall comply with all requirements of this chapter.

Especially for many older products gastritis symptoms heartburn buy line prevacid, clinical trial exposure may be minimal over a 5 year period and in any event will be far exceeded by market exposure gastritis hiv discount 30 mg prevacid overnight delivery. It is proposed that: Clinical trial data should only be included if the data suggest a signal or are relevant to any suspected changes in the benefit-risk relationship for the product gastritis diet webmd discount prevacid 30 mg fast delivery. It must be emphasized that companies must still review and analyze all the case histories received in the time period to search for safety signals gastritis diet list purchase prevacid on line. When the line listing is omitted gastritis diet xenadrine cheap prevacid on line, presentation and analysis of the case reports through the summary tabulation(s) becomes especially im2 In principle, company-generated line listings may become moot in the future for those regulators able and willing to receive individual case reports electronically, especially on an ongoing basis. However, it is uncertain when such a situation will prevail and furthermore there will presumably always be some authorities requiring that line listings be submitted. There is no magic number that qualifies as defining a very large, unwieldy volume for a line listing; 200 is chosen arbitrarily as a reasonable cut-off. Clearly, for any event involving a signal or key safety issue, all relevant cases should be line-listed independent of any cut-off number. However, care must be taken to ensure that medically important distinctions are not overlooked by using terms at too high a level. Also, it is important that when possible, diagnoses rather than (or in addition to) signs and symptoms be identified in summary tabulations. Presentation and assessment in terms of listedness (rather than by serious vs non-serious) under each system organ class may be the most meaningful approach. A large number of clinical or non-clinical studies may have been conducted during a five-year reporting period. Similarly, a comprehensive literature search for an active drug could potentially produce several hundred papers. The inclusion and discussion of literature reports should be selective and focus on publications relevant to safety findings, independent of listedness. The key question, of course, is how to define little or no new information or findings. The following criteria are suggested, all of which ought to be considered: (1) No serious unlisted cases have been received, there are very few serious listed cases. As usual, a list of any completed studies that focussed on safety should be mentioned. It is not uncommon for local regulators to request changes to safety information in a data sheet. Therefore, it is incumbent on the company to use its judgment on whether local label alterations constitute ``regulatory actions for safety reasons. While the example is for an annual report, the same format could be used for 6 month and 5 year reports as well. Please note that the example purposely does not technically satisfy all the suggested criteria but is included to illustrate how a special situation can be handled. Proposals Relating to Frequency and Timing of Reporting As already discussed, there are circumstances in which the usual reporting schedule as designated by many regulators does not or cannot readily apply. In order to avoid the need for a company to prepare a separate one-year report when the product is still under a 6-monthly reporting cycle, a need has been expressed by regulators for some other way to tie together (``bridge') the two 6-month reports (thus, a Summary Bridging Report). One possible practical approach to help overcome the difficulty associated in general with timing and frequency of reporting for new drugs would be to continue with a six-monthly or annual schedule indefinitely, especially if new indications or formulations are likely to be introduced over the years. However, whether such an approach is suitable will depend on the number and types of products a company sells, business processes, resources, and other factors. For example, it may be used to cover four six-month reports in lieu of a separate two-year report, or five separate annual reports for a new, cumulative 5-year report, including reports for license renewal in Europe. The bridging report would obviously cross reference the covered individual reports and, although some of them may have been previously submitted as part of a shorter reporting cycle, the actual reports should be appended. The submission of a summary bridging report should not by itself indicate a need for a new review of the data. The summary bridging report itself, however, is not the tool for such interim (addendum) reporting. It may not be appropriate to structure this chronologically but according to issues and the most recent measures taken to manage them. Exposure data - an estimate of the total number of patients exposed in the time period covered by the bridging report (including from clinical trials if appropriate). Overall Safety Evaluation and Conclusion - mention only key unresolved issues and possible measures to address the problem. Until then, an expedient approach is needed to manage the inconsistencies in harmonization without adding an undue burden for both companies and regulators in the preparation and review of extra reports. They should not be required routinely but should be prepared only on special regulatory request. However, recognizing the limitations of pharmacovigilance resources, the Working Group proposes the following minimum information for inclusion in an addendum report. If the volume of reports is high, as already recommended consideration should be given to excluding the line-listing. Conclusion - a brief overview of the new cases included and a comment on whether or not they are in line with the known safety profile of the product. In summary, the purpose of an addendum report is to supplement, not replace, the basic reporting cycle. Subsequent five-year license renewal reports would be submitted at five year intervals following the submission of the first ``five year' report (that really covers, as stated, 4. It was agreed that it should be acceptable to provide multiples of six-monthly or annual reports that have already been prepared by the company to cover the period requested by individual regulatory authorities to comply with their own local requirements. However, it was considered necessary that the reports be accompanied by a document chronologically summarizing the information contained in the series of reports (a Summary Bridging Report as described above). This same concept is applicable for all five-year license renewals subsequent to the first one. Individual regulators may define what is meant by ``old' products; there is no general definition. However, it must be recognized that such a conversion for existing drugs is time consuming, expensive and not very practical especially for global companies with extensive portfolios and line extensions; each attempt requires a variation application within each country. It is also necessary, as usual, to indicate which countries, if any, have refused approval or license renewal, or in which the product has been withdrawn for safety reasons, along with an explanation. It is also important to remember that discussion of serious unlisted cases should cover cumulative data. There are two general situations for which regulators must consider whether it is necessary to ask companies to revert to a six-month reporting interval when a longer period (one or five years. The safety profile of a product is best characterized according to the number and types of patients treated; reporting frequency should be influenced by the extent of clinical knowledge of the product. For such products, it is recommended that regulators in the new market accept a summary tabulation (with or without supporting line listings) of spontaneously reported adverse events over the shorter periods in the new market (say every 6 months for a reasonable length of time, perhaps two years). For such short-interval data submissions, review of the worldwide literature is not considered necessary, especially for older products already available generically in major markets. For both (a) and (b), in any event, consideration for restarting the clock should be discussed between the regulators and the company preferably prior to but certainly no later than time of approval of the relevant application dossier. There is a need for a greater degree of flexibility in the timeline to ensure that not only all the relevant safety data are covered (linelistings, tabulations, literature, studies) but appropriate analysis and interpretation of the data are made (overall analysis and conclusions). Number of reports for the reporting period (high volume versus low volume) Drug activity. However, for a recently introduced product with multiple safety issues that is indicated for a complicated disease syndrome and is associated with a high volume of adverse event reports, a longer preparation time. When a company realizes that 60 days may not suffice, it should alert regulators to a possible delay and provide an explanation; this will allow the regulators to facilitate their own review planning, especially if it involves multiple agencies. It would provide the reader, especially the regulators, with a description of the basic content and most important findings as a guide to the full document. Introduction Obtaining and understanding patient exposure information (the ``denominator') is important for both manufacturers and regulatory authorities to help assess the benefits and risks of any medicinal product and to place such information in proper perspective. In general, appropriate use of denominator data is part of good epidemiological and public health practices. There are many difficulties associated with obtaining and using the relevant data, particularly from sources outside the relatively controlled environment of clinical trials or other studies in which the size and characteristics of the treated populations are known with considerable accuracy. Estimating person-use for marketed drugs usually relies on gross approximations, especially for non-prescription products, and represents more of an art than a science. Of course, there are exceptions for which accurate counts are possible, such as administration of a single-dose treatment in hospital or clinic under direct supervision, or in vaccination programs. The level of detail and accuracy required for exposure statistics will depend on the intended use of the data. A simple denominator that defines broad exposure, useful for routine periodic safety reporting, might need only a count or estimate of all exposed subjects, without regard to their characteristics. On the other hand, an analysis of a subgroup, defined by age and/or gender, for example, might require considerably more effort. Although it may be useful, even important, to obtain breakdowns of patient exposure according to the many covariates that define user groups (see below), it is usually very difficult to obtain such detailed and extensive data outside a clinical trial environment. However, in this context, the word should be regarded as synonymous with ``denominator,' a measure of the number of patients in a population that are treated with a medicine. The dimension of time on drug is obviously important in any real measure of drug-exposure. It was designed to collect information on sources of denominator information, exposure metrics, time period covered by exposure information, processes for compiling exposure data, circumstances surrounding the determination of exposure data, and regulatory experience with exposure data; the questionnaire and results are presented in Appendix 15 but are summarized here. Only 20% of the companies agreed that marketing data were sufficiently complete and accurate for the purpose of estimating drug exposure. Information on particulars such as duration of treatment, age or gender of exposed population, or the medical specialty of the prescriber, were not available through traditional sales information and when needed had to be obtained from other sources. Although the majority of companies were aware of one or more of the various non-company databases mentioned in the questionnaire. The most commonly used type of unit for describing marketed drug use was patient-time. However, most companies did not or were unable to routinely stratify patient exposure by age or gender. Estimates of off-label use were made by 5 (19%) companies but by three of the four regulators. However, most respondents did report attempts to collect and assess data relevant to overdose. They also regarded the use and interpretation of exposure data by Companies as ``good' (1/4) or ``poor' (3/4). For clinical trials and other studies in which the treated populations are usually well characterized by their nature and size, there are established methods for calculating and representing ``drug exposure' (something that is deceptively simple, but can actually be quite complicated);2 this topic will be discussed briefly. There is another aspect to the concepts of numerator and denominator, particularly when attempting to use spontaneous report data for signal detection. One important statistic that is always valuable is the background rate for a condition within a specific population. For example, when faced with a case series involving a new, especially unusual, adverse medical condition, an estimate of the background rate for the type of population exposed to the drug can be very useful. Such data, when available, can be found in compilations of national health statistics databases. Several cases of an unusual adverse event in a population in which that event is very rare would suggest at least the possibility of a drug signal. In addition to helping place into perspective the numbers and types of safety reports over time, the data also are useful for detecting trends in drug use. Evaluation of Safety Data from Controlled Clinical Trials: the Clinical Principles Explained. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs. One particular gap is the absence of hospital-based (inpatient exposure) statistics from the major use-monitoring sources. Thus, in the absence of special situations (important safety signal, for example), an overall estimate expressed in customary terms and units (see below) is adequate. Available sources of data and methods for estimating drug use depend on the setting. In clinical trials, compassionate treatment (named-patient) programs, observational studies and other situations in which a cohort of subjects is readily defined, the number of patients treated with a drug is easily obtained. However, the proper measure of patient-exposure as a function of time, demographics, and other parameters requires care. It should also be remembered that for complete estimates of drug use, data covering generic products and non-prescription use (when the same product is sold over-the-counter and by prescription in different locations) may have to be considered. The data on marketed products do not appear to follow a normal distribution, which could be due to a variety of causes. For marketed drugs, data sources and services can be classified as follows: the Manufacturer (or Distributor): amount sold or put into commercial circulation; results of sponsored surveys by companies are also useful 4 For details on the various confounders and biases associated with both numerators and denominators, see: Sachs, R. An Evaluation of Spontaneous Adverse Reaction Monitoring Systems, American Journal of Medicine, supplement 5B, 81:49-55, 1986; Baum, S. Also of interest are the many private and public secondary databases or collections of medical records that can provide patient-use data as well as offer the opportunity to evaluate hypotheses or generally to conduct retrospective studies on a designated population. Technical Considerations Covariates Defining a Treated Population the amount of data necessary to characterize a treated population depends on the circumstances and intended use of the information: from a crude overall estimation (order of magnitude) to specifically defined and highly detailed subsets. Ideally, it would be possible to characterize a treated population in terms of many properties (see Table 1). Typically, the level of complexity for defining a population is highly dependent on the disease(s) or condition(s) treated, the number and types of dosage forms, doses and dosing regimens in use, and other general factors. A Comparison of Data Sources for Drug Exposure Ascertainment in Pharmacoepidemiologic Studies with Emphasis on Self-Reported Information, Pharmacoepidemiology and Drug Safety, 6:215-218, 1997.

Presently common views are as follows: Children above the age of 2 years can be corrected by implantation of posterior chamber intraocular lens during surgery gastritis symptoms light headed prevacid 15 mg online. Children below the age of 2 years should preferably be treated by extended wear contact lens gastritis symptoms upper right quadrant pain cheap prevacid 30 mg buy. Present trend is to do primary implantation at the earliest possible (2-3 months) specially in unilateral cataract gastritis diet 5 days order prevacid with a visa. In children between 2-8 years of age 10% undercorrection from the calculated biometric power is recommended to counter the myopic shift eosinophilic gastritis symptoms order prevacid online pills. It is the central theme forms chronic gastritis sydney classification purchase discount prevacid on-line, the cortical (soft cataract) and the nuclear (hard cataract). The cortical senile cataract may start as cuneiform (more commonly) or cupuliform cataract. In general, the predominant form can be given as cuneiform 70 percent, nuclear 25 percent and cupuliform 5 percent. Though its precise etiopathogenesis is not clear, the various factors implicated are as follows: A. While, in acquired cataract, opacification occurs due to degeneration of the already formed normal fibres. The exact mechanism and reasons for the degeneration of lens fibres are yet not clear. However, in general any factor, physical, chemical or biological, which disturbs the critical intra and extracellular equilibrium of water and electrolytes or deranges the colloid system within the lens fibres, tends to bring about opacification. The factors responsible for disturbing such an equilibrium of the lens fibres vary in different types of acquired cataracts and shall be discussed with the individual type. An association with prior episode of severe dehydrational crisis (due to diarrhoea, cholera etc. Smoking causes accumulation of pigmented molecules-3 hydroxykynurinine and chromophores, which lead to yellowing. The condition is usually bilateral, but almost always one eye is affected earlier than the other. Morphologically, the senile cataract occurs in two cataract is used when the cataractous changes similar to senile cataract occur before 50 years of age. As mentioned above because of influence of heredity, the cataractous changes may occur at an earlier age in successive generations. Myotonic dystrophy is associated with posterior subcapsular type of presenile cataract. Atopic dermatitis may be associated with presenile cataract (atopic cataract) in 10% of the cases. It is Stages of maturation [A] Maturation of the cortical type of senile cataract 1. The earliest senile change is demarcation of cortical fibres owing to their separation by fluid. This phenomenon of lamellar separation can be demonstrated by slit-lamp examination only. Two distinct types of senile cortical cataracts can be recognised at this stage: (a) Cuneiform senile cortical cataract. These extend from equator towards centre and in early stages can only be demonstrated after dilatation of the pupil. These opacities are present both in anterior and posterior cortex and their apices slowly progress towards the pupil. On oblique illumination these present a typical radial spoke-like pattern of greyish white opacities. Here a saucershaped opacity develops just below the capsule basically different in nuclear and cortical senile cataracts. Its main biochemical features are decreased levels of total proteins, amino acids and potassium associated with increased concentration of sodium and marked hydration of the lens, followed by coagulation of proteins. In it the usual degenerative changes are intensification of the agerelated nuclear sclerosis associated with dehydration and compaction of the nucleus resulting in a hard cataract. There may or may not be associated deposition of pigment urochrome and/or melanin derived from the amino acids in the lens. Flow chart depicting probable course of events involved in occurence of cortical senile cataract. Diagrammatic depiction of Immature senile cataract (cuneiform type): A, as seen by oblique illumination; B, in optical section with the beam of the slit-lamp. Cupuliform cataract lies right in the pathway of the axial rays and thus causes an early loss of visual acuity. The hypermature cataract may occur in any of the two forms: (a) Morgagnian hypermature cataract: In some patients, after maturity the whole cortex liquefies and the lens is converted into a bag of milky fluid. Morgagnian hypermature senile cataract: A, diagrammatic depiction; B, Clinical photograph. The anterior capsule is wrinkled and thickened due to proliferation of anterior cells and a dense white capsular cataract may be formed in the pupillary area. The nucleus may become diffusely cloudy (greyish) or tinted (yellow to black) due to deposition of pigments. In practice, the commonly observed pigmented nuclear cataracts are either amber, brown (cataracta brunescens) or black (cataracta nigra) and rarely reddish (cataracta rubra) in colour. An opacity of the lens may be present without causing any symptoms; and may be discovered on routine ocular examination. One of the earliest visual disturbances with the cataract is glare or intolerance of bright light; such as direct sunlight or the headlights of 4. The amount of glare or dazzle will vary with the location and size of the opacity. It occurs due to irregular refraction by the lens owing to variable refractive index as a result of cataractous process. These may be perceived by some patients owing to breaking of white light into coloured spectrum due to presence of water droplets in the lens. Image blur, distortion of images and misty vision may occur in early stages of cataract. Nuclear cataract: A, cataracta brunescens; B, cataracta nigra; and C, Cataracta rubra. In patients with nuclear sclerosis, distant vision deteriorates due to progressive index myopia. As opacification progresses, vision steadily diminishes, until only perception of light and accurate projection of rays remains in stage of mature cataract. Following examination should be carried out to look for different signs of cataract: 1. It reveals colour of the lens in pupillary area which varies in different types of cataracts (Table 8. When an oblique beam of light is thrown on the pupil, a crescentric shadow of pupillary margin of the iris will be formed on the greyish opacity of the lens, as long as clear cortex is present between the opacity and the. Diagrammatic depiction of iris shadow in: immature cataract (A) and no iris shadow in mature cataract (B). When lens is completely transparent or completely opaque, no iris shadow is formed. Partial cataractous lens shows black shadow against the red glow in the area of cataract. The examination reveals complete morphology of opacity (site, size, shape, colour pattern and hardness of the nucleus). Grading of nucleus hardness in a cataractous lens is important for setting the parameters of machine in phacoemulsification technique of cataract extraction. The hardness of the nucleus, depending upon its colour on slit-lamp examination, can be graded as shown in Table 8. No black spots are glow are observed on seen against red glow distant direct ophthalmoscopy 5. Mature senile cataract can be differentiated from other causes of white pupillary reflex (leukocoria) as shown in Table 8. These proteins may act as antigens and induce antigenantibody reaction leading to uveitis. Multicoloured crystals or small discrete white flecks of opacities are formed in the cortex which seldom mature. It is a rare condition, usually occurring in young adults due to osmotic over-hydration of the lens. Initially a large number of fluid vacuoles appear underneath the anterior and posterior capsules, which is soon followed by appearance of bilateral snowflake-like white opacities in the cortex. Systemic features of this syndrome are mental retardation, dwarfism, osteomalacia, muscular hypotonia and frontal prominence. Therefore, to avoid confusion and controversy, preferably, the term secondary cataract should be discarded. The lens changes may be reversible and occurrence of cataract may be prevented, if milk and milk products are eliminated from the diet when diagnosed at an early stage. Therefore, any condition in which the ocular circulation is disturbed or in which inflammatory toxins are formed, will disturb nutrition of the crystalline lens, resulting in development of complicated cataract. These include uveal inflammations (like iridocyclitis, parsplanitis, choroiditis), hypopyon corneal ulcer and endophthalmitis. Degenerative conditions such as retinitis pigmentosa and other pigmentary retinal dystrophies and myopic chorioretinal degeneration. The underlying cause here is probably the embarrassment to the intraocular circulation, consequent to the raised pressure. Intraocular tumours such as retinoblastoma or melanoma may give rise to complicated cataract in late stages. Other toxic cataracts Other drugs associated with fine toxic cataracts are amiodarone, chlorpromazine, busulphan, gold and allopurinol. Slowly the opacity spreads in the rest of the cortex, and finally the entire lens becomes opaque, giving chalky white appearance. Infrared (heat) cataract Prolonged exposure (over several years) to infra-red rays may cause discoid posterior subcapsular opacities and true exfoliation of the anterior capsule. Irradiation cataract Posterior subcapsular opacities are associated with the use of topical as well as systemic steroids. The exact relationship between dose and duration of corticosteroid therapy with the development of cataract is still unclear. Therefore, it is recommended that all patients with diseases requiring prolonged corticosteroids therapy should be regularly examined on slit-lamp by an ophthalmologist. Miotics-induced cataract Exposure to X-rays, -rays or neutrons may be associated with irradiation cataract. Ultraviolet radiation cataract Ultraviolet radiation has been linked with senile cataract in many studies. The cataract usually starts as punctate subcapsular opacities which mature rapidly. Atopic dermatitis is the most common cutaneous disease associated with cataract (Atopic cataract). However, certain non-surgical measures may be of help, in peculiar circumstances, till surgery is taken up. Non-surgical measures Use of dark goggles in patients with central opacities is of great value and comfort when worn outdoors. The patients with a small axial cataract, frequently may benefit from pupillary dilatation. In acquired cataracts, thorough search should be made to find out the cause of cataract. Some common examples include: Adequate control of diabetes mellitus, when discovered. Removal of cataractogenic drugs such as corticosteroids, phenothiazenes and strong miotics, may delay or prevent cataractogenesis. Removal of irradiation (infrared or X-rays) may also delay or prevent cataract formation. Early and adequate treatment of ocular diseases like uveitis may prevent occurrence of complicated cataract. Many commercially available preparations containing iodide salts of calcium and potassium are being prescribed in abundance in early stages of cataract (especially in senile cataract) in a bid to delay its progression. Role of vitamin E and aspirin in delaying the process of cataractogenesis is also mentioned. Measures to improve vision in the presence of incipient and immature cataract may be of great solace to the patient. These include: Refraction, which often changes with considerable rapidity, should be corrected at frequent intervals. Patients with peripheral opacities (pupillary area still free), may be instructed to use brilliant illumination. So, an individual should be operated for cataract, when the visual handicap becomes a significant deterrent to the maintenance of his or her usual life-style. Sometimes patients may be comfortable from the visual point (due to useful vision from the other eye or otherwise) but may be advised cataract surgery due to medical grounds such as Lens induced glaucoma, Phacoanaphylactic endophthalmitis and Retinal diseases like diabetic retinopathy or retinal detachment, treatment of which is being hampered by the presence of lens opacities. Sometimes patient with mature cataract may insist for cataract extraction (even with no hope of getting useful vision), in order to obtain a black pupil. Preoperative evaluation Once it has been decided to operate for cataract, a thorough preoperative evaluation should be carried out before contemplating surgery. General medical examination of the patient to exclude the presence of serious systemic diseases especially: diabetes mellitus; hypertension and cardiac problems; obstructive lung disorders and any potential source of infection in the body such as septic gums, urinary tract infection etc. The retinal function must be explored since, if it is defective, operation will be valueless, and patient must be warned of the prognosis, to avoid unnecessary disappointment and medicolegal problems. Many sophisticated retinal function tests have been developed, but light perception must be present, if there is to be any potential for useful vision.

However gastritis neurological symptoms order prevacid 15 mg free shipping, it is definitely linked with (i) heredity and (ii) general growth process high fiber diet gastritis buy discount prevacid on line. It is now confirmed that genetic factors play a major role in the etiology gastritis diet mango prevacid 15 mg purchase otc, as the progressive myopia is (i) familial; (ii) more common in certain races like Chinese gastritis diet on a budget purchase prevacid 30 mg with mastercard, Japanese gastritis green tea purchase online prevacid, Arabs and Jews, and (iii) uncommon among Negroes, Nubians and Sudanese. It is presumed that heredity-linked growth of retina is the determinant in the development of myopia. Role of general growth process, though minor, cannot be denied on the progress of myopia. Lengthening of the posterior segment of the globe commences only during the period of active growth and probably ends with the termination of the active growth. Further, due to progressive degenerative changes, an uncorrectable loss of vision may occur. The eyes are often prominent, appearing elongated and even simulating an exophthalmos, especially in unilateral cases. The elongation of the eyeball mainly affects the posterior pole and surrounding area; the part of the eye anterior to the equator may be normal. Fundus examination reveals following characteristic signs: (a) Optic disc appears large and pale and at its temporal edge a characteristic myopic crescent is present. Sometimes peripapillary crescent encircling the disc may be present, where the choroid and retina is distracted away from the disc margin. A super-traction crescent (where the retina is pulled over the disc margin) may be present on the nasal side. These are characterised by white atrophic patches at the macula with a little heaping up of pigment around them. In an advanced case there occurs total retinal atrophy, particularly in the central area. Complications (i) Retinal detachment; (ii) complicated cataract; (iii) vitreous haemorrhage; (iv) choroidal haemorrhage (v) Strabismus fixus convergence. Optical treatment of myopia constitutes prescription of appropriate concave lenses, so. Thus, correction of this astigmatism will require the concave cylinders at 180° ± 20° or convex cylindrical lens at 90° ± 20°. Against-the-rule astigmatism refers to an astigmatic condition in which the horizontal meridian is more curved than the vertical meridian. Therefore, correction of this astigmatism will require the presciption of convex cylindrical lens at 180° ± 20° or concave cylindrical lens at 90° ± 20° axis. Oblique astigmatism is a type of regular astigmatism where the two principal meridia are not the horizontal and vertical though these are at right angles to one another. In this type of regular astigmatism the two principal meridia are not at right angle to each other. Optics of regular astigmatism Astigmatism is a type of refractive error wherein the refraction varies in the different meridia. Index astigmatism may occur rarely due to variable refractve index of lens in different meridia. Types of regular astigmatism As already mentioned, in regular astigmatism the parallel rays of light are not focused on a point but form two focal lines. The shape of bundle of rays at different levels (after refraction through astigmatic surface) is described on page 25. Refractive types of regular astigmatism Depending upon the axis and the angle between the two principal meridia, regular astigmatism can be classified into the following types: 1. In this type the two principal meridia are placed at right angles to one Depending upon the position of the two focal lines in relation to retina, the regular astigmatism is further classified into three types: 1. Simple astigmatism, wherein the rays are focused on the retina in one meridian and either in front (simple myopic astigmatism ­. In this type the rays of light in both the meridia are focused either in front or behind the retina and the condition is labelled as compound myopic or compound hypermetropic astigmatism, respectively. Mixed astigmatism refers to a condition wherein the light rays in one meridian are focused in front and in other meridian behind the retina. Symptoms Symptoms of regular astigmatism include: (i) defective vision; (ii) blurring of objects; (iii) depending upon the type and degree of astigmatism, objects may appear proportionately elongated; and (iv) asthenopic symptoms, which are marked especially in small amount of astigmatism, consist of a dull ache in the eyes, headache, early tiredness of eyes and sometimes nausea and even drowsiness. Oval or tilted optic disc may be seen on ophthalmoscopy in patients with high degree of astigmatism. Keratometry and computerized corneal topotograpy reveal different corneal curvature in two different meridia in corneal astigmatism (see page 554) 3. These tests are useful in confirming the power and axis of cylindrical lenses (see pages 555, 556). Types of astigmatism: simple myopic (A); simple hypermetropic (B); compound myopic (C); compound hypermetropic (D); and mixed (E). Optical treatment of regular astigmatism comprises the prescribing appropriate cylindrical lens, discovered after accurate refraction. Spectacles with full correction of cylindrical power and appropriate axis should be used for distance and near vision. Rigid contact lenses may correct upto 2-3 of regular astigmatism, while soft contact lenses can correct only little astigmatism. In order to maintain the correct axis of toric lenses, ballasting or truncation is required. Surgical treatment is indicated in extensive corneal scarring (when vision does not improve with contact lenses) and consists of penetrating keratoplasty. Etiological types the optical state with equal refraction in the two eyes is termed isometropia. A difference of 1 D in two eyes causes a 2 percent difference in the size of the two retinal images. Curvatural irregular astigmatism is found in patients with extensive corneal scars or keratoconus. Index irregular astigmatism due to variable refractive index in different parts of the crystalline lens may occur rarely during maturation of cataract. Symptoms of irregular astigmatism include: Defective vision, Distortion of objects and Polyopia. Photokerotoscopy and computerized corneal topography give photographic record of irregular corneal curvature. Optical treatment of irregular astigmatism consists of contact lens which replaces the anterior surface of the cornea for refraction. In this, one eye is normal (emmetropic) and the other either myopic (simple myopic anisometropia) or hypermetropic (simple hypermetropic anisometropia). Binocular single vision is present in small degree of anisometropia (less than 3). Diagnosis It is made after retinoscopic examination in patients with defective vision. Aniseikonic glasses are also available, but their clinical results are often disappointing. Other modalities of treatment include: Intraocular lens implantation for uniocular aphakia. Refractive corneal surgery for unilateral high myopia, astigmatism and hypermetropia. In it image distortion increases progressively in both directions, as seen with high plus correction in aphakia. In it image distortion decreases progressively in both directions, as seen with high minus correction. Diplopia due to difficult binocular vision when the difference in images of two eyes is more than 5 percent 3. Treatment Aniseikonia is defined as a condition wherein the images projected to the visual cortex from the two retinae are abnormally unequal in size and/or shape. Optical aniseikonia may be corrected by aniseikonic glasses, contact lenses or intraocular lenses depending upon the situation. However, our eyes have been provided with a unique mechanism by which we can even focus the diverging rays coming from a near object on the retina in a bid to see clearly. Types of aniseikonia: A, spherical; B, cylindrical; C, prismatic; D, pin-cushion; E, barrel distortion; and F, oblique distortion. At rest the radius of curvature of the anterior surface of the lens is 10 mm and that of posterior surface is 6 mm. In accommodation, the curvature of the posterior surface remains almost the same, but the anterior surface changes, so that in strong accommodation its radius of curvature becomes 6 mm. Mechanism of accommodation According to von Helmholtz capsular theory in humans the process of accommodation is achieved by a change in the shape of lens as below. Contraction of the ciliary muscle causes the ciliary ring to shorten and thus releases zonular tension on the lens capsule. The lens then alters its shape to become more convex or conoidal (to be more precise). The lens assumes conoidal shape due to configuration of the anterior lens capsule which is thinner at the center and thicker at the periphery. Far point and near point the nearest point at which small objects can be seen clearly is called near point or punctum proximum and the distant (farthest) point is called far point or punctum remotum. To understand the pathophysiology of presbyopia a working knowledge about accommodation (as described above) is mandatory. As we know, in an emmetropic eye far point is infinity and near point varies with age (being about 7 cm at the age of 10 years, 25 cm at the age of 40 years and 33 cm at the age of 45 years). Therefore, at the age of 10 years, amplitude of accommodation (A) = 100 7 Anomalies of accommodation are not uncommon. These include: (1) Presbyopia, (2) Insufficiency of accommodation, (3) Paralysis of accommodation, and (4) Spasm of accommodation. After the age of 40 years, the near point of accommodation recedes beyond the normal reading or working range. Decrease in the accommodative power of crystalline lens with increasing age, leading to presbyopia, occurs due to: 1. Age-related changes in the lens which include: Decrease in the elasticity of lens capsule, and Progressive, increase in size and hardness (sclerosis) of lens substance which is less easily moulded. Age related decline in ciliary muscle power may also contribute in causation of presbyopia. Near point should be fixed by taking due consideration for profession of the patient. The weakest convex lens with which an individual can see clearly at the near point should be prescribed, since overcorrection will also result in asthenopic symptoms. Another important complaint of the patient is difficulty in threading a needle etc. Asthenopic symptoms due to fatigue of the ciliary muscle are also complained after reading or doing any near work. Weakness of ciliary muscle due to systemic causes of muscle fatigue such as debilitating illness, anaemia, toxaemia, malnutrition, diabetes mellitus, pregnancy, stress and so on. Clinical features All the symptoms of presbyopia are present, but those of asthenopia are more prominent than those of blurring of vision. The treatment of presbyopia is the prescription of appropriate convex glasses for near work. A rough guide for providing presbyopic glasses in an emmetrope can be made from the age of the patient. However, the presbyopic add should be estimated individually in each eye in order to determine how much is necessary to provide a comfortable range. Find out the presbyopic correction needed in each eye separately and add it to the distant correction. Paralysis of accommodation also known as cycloplegia refers to complete absence of accommodation. Internal ophthalmoplegia (paralysis of ciliary muscle and sphincter pupillae) may result from neuritis associated with diphtheria, syphilis, diabetes, alcoholism, cerebral or meningeal diseases. Paralysis of accommodation as a component of complete third nerve paralysis may occur due to intracranial or orbital causes. Photophobia (glare) due to accompanying dilatation of pupil (mydriasis) is usually associated with blurring of near vision. Examination reveals abnormal receding of near point and markedly decreased range of accommodation. Self-recovery occurs in drug-induced paralysis and in diphtheric cases (once the systemic disease is treated). Relaxation of ciliary muscle by atropine for a few weeks and prohibition of near work allow prompt recovery from spasm of accommodation. It is a common, cheap and easy method of prescribing corrective lenses in patients with refractive errors and presbyopia. Some important aspects of the spectacles are as follows: Lens materials Spasm of accommodation refers to exertion of abnormally excessive accommodation. Spontaneous spasm of accommodation is occasionally found in children who attempt to compensate for a refractive anomaly that impairs their vision. It usually occurs when the eyes are used for excessive near work in unfavourable circumstances such as bad illumination bad reading position, lowered vitality, state of neurosis, mental stress or anxiety. It is ground to the appropriate curvature and then polished to await the final cutting that will enable it to fit the desired spectacle frame. They are unbreakable and light weight but have the disadvantages of being readily scratched and warped. In this type the central portion is corrective and the peripheral surfaces are parallel to one another. Aspheric lenses are also used to make high plus aphakic lenses by modifying the lens curvature peripherally to reduce aberrations and provide better peripheral vision.

Buy 15 mg prevacid overnight delivery. What is GASTRITIS? What does GASTRITIS mean? GASTRITIS causes signs symptoms & treatment.

References

• Mehta MC, Jain AC, Billie M. Combined effects of alcohol and nicotine on cardiovascular performance in a canine model. J Cardiovasc Pharmacol 1998;31:930.
• Ouattara A, Boccara G, Kockler U, et al: Remifentanil induces systemic arterial vasodilation in humans with a total artificial heart, Anesthesiology 100:602, 2004.
• Williams GR Jr, Spencer FC. The clinical use of hypothermia following cardiac arrest. Ann Surg. 1958;148(3):462-468.
• Stanley TH, Bennett GM, Loeser EA, et al: Cardiovascular effects of diazepam and droperidol during morphine anesthesia, Anesthesiology 44:255, 1976.
• Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal. 1999;21(2): 383-392.
• Ertel W, Oberholzer A, Platz A, et al. Incidence and clinical pattern of the abdominal compartment syndrome after idamage controli laparotomy in 311 patients with severe abdominal and/or pelvic trauma. Crit Care Med. 2000;28:1747-1753.
• Katzenstein AL, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002; 26(12):1567-77.